NeOnc Technologies Holdings Inc. has entered a strategic partnership with Quazar Investment, involving a $50 million agreement aimed at advancing the company's global reach and scientific innovation. Under the terms of the deal, Quazar will acquire 1.4 million shares of NeOnc at $25 per share, accounting for a $35 million anchor position, with the remaining $15 million dedicated to Phase 2B clinical trials and infrastructure development across the UAE and MENA region. The partnership is set to enhance NeOnc's therapeutic footprint, pending the completion of legal and capital formation processes within 120 days. This collaboration marks a significant step in expanding access to neuro-oncology treatments in the region.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。